There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Apellis Pharmaceuticals (APLS – Research Report) and Bluebird Bio (BLUE – Research Report) with bullish sentiments.
Apellis Pharmaceuticals (APLS)
Robert W. Baird analyst Colleen M. Kusy reiterated a Buy rating on Apellis Pharmaceuticals yesterday and set a price target of $100.00. The company’s shares closed last Thursday at $58.78.
According to TipRanks.com, Kusy is a 3-star analyst with an average return of
Apellis Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $83.73, implying a 43.2% upside from current levels. In a report issued on March 19, J.P. Morgan also reiterated a Buy rating on the stock with a $79.00 price target.
See the top stocks recommended by analysts >>
Bluebird Bio (BLUE)
In a report issued on March 26, Jack Allen from Robert W. Baird maintained a Buy rating on Bluebird Bio, with a price target of $7.00. The company’s shares closed last Thursday at $1.28, close to its 52-week low of $0.88.
According to TipRanks.com, Allen is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on Bluebird Bio is a Hold with an average price target of $3.87, implying a 188.8% upside from current levels. In a report issued on March 26, Barclays also maintained a Buy rating on the stock with a $8.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on APLS:
- Apellis appoints Philip Ferrone as chief medical retina advisor
- Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor
- Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- EyePoint appoints Ribeiro as Chief Medical Officer
- Apellis price target raised to $89 from $87 at UBS
